SLA welcomes the £100m GSK investment in Scotland
Released: Thursday 22nd March 2012
More than £100m investment confirmed for GSK manufacturing in Scotland
GSK has announced that it will invest more than £100m across its two manufacturing sites in Scotland. This includes new funding at Montrose to enable the manufacture of key materials for GSK’s portfolio of respiratory medicines. Investment will also be made at Montrose to produce aluminium adjuvants, which are high-tech agents used in the manufacture of vaccines to help stimulate the body’s immune system.
GSK is the world’s largest vaccine company and this is the first time a UK GSK site will participate in the company’s vaccine manufacturing supply chain. At Irvine, GSK will increase production capacity for antibiotics, reflecting growing demand for these medicines in Emerging Markets. GSK will also invest in sustainable green energy production and environmentally friendly manufacturing technologies at both sites.